If a weekly Leqembi IQLIK injection is missed, give the prescribed dose as soon as possible, provided no more than six days have passed, and then give the next dose on the original scheduled day. Do not double the dose or create a new schedule. If more than six days have passed, the family is unsure whether the injection was completed, or treatment was paused for a medical reason, contact the prescribing clinician before giving another dose. These instructions apply to subcutaneous Leqembi IQLIK; a missed intravenous infusion requires coordination with the infusion center.
For example, if the regular injection day is Monday and the family discovers the missed dose on Thursday, the dose can generally be given Thursday and the next dose remains due the following Monday. If the missed dose is discovered after the six-day window, the family should not improvise by injecting two doses, shifting the schedule, or treating the next injection as an automatic catch-up dose. The current Leqembi dosing instructions direct patients to resume the original weekly schedule after an eligible catch-up dose. A missed appointment may sound like a routine scheduling problem, but Leqembi has important neurological risks and several dosing formats. Families should first confirm whether they are managing an at-home injection, a clinic-administered injection, or an intravenous infusion, then check the date, symptoms, storage conditions, and any instructions previously given by the treatment team.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Should Alzheimer’s Families Do First After a Missed Leqembi Injection?
- Understanding the Six-Day Leqembi Missed-Dose Window
- When a Missed Injection Is Really a Safety Hold
- A Practical Family Plan for Missed Leqembi Doses
- Common Leqembi Injection Problems That Need a Clinician’s Advice
- Storage and Autoinjector Problems Can Create a Missed Dose
- What Emergency Teams Need to Know About Leqembi
- Frequently Asked Questions
What Should Alzheimer’s Families Do First After a Missed Leqembi Injection?
Start by writing down the regular dosing day, the date and time the dose should have been given, and the current date and time. Check the treatment log, used-autoinjector container, medication supply, and any caregiver messages to confirm that the dose was genuinely missed. If two relatives share medication duties, one should not give an injection simply because the other person cannot immediately recall giving it. An uncertain dose is different from a confirmed missed dose and requires a call to the prescriber or dispensing pharmacy. Next, identify the route of treatment. leqembi IQLIK is a subcutaneous formulation that may be administered at home by a trained patient or caregiver.
Intravenous Leqembi is delivered through a vein, usually at an infusion center. For a missed infusion, the FDA-approved prescribing information says the next dose should be administered as soon as possible, but the clinic must arrange that dose and determine subsequent appointment dates. Families should never try to substitute an at-home product for an infusion or vice versa without the prescriber’s direction. The FDA prescribing information provides separate missed-dose instructions for the two routes. Confirm that the missed injection was accidental rather than part of a clinician-ordered interruption. A dose withheld because of an abnormal MRI, possible amyloid-related imaging abnormalities, an allergic reaction, or a serious illness should not be restarted under the ordinary six-day rule. In that situation, “missed” may actually mean “medically suspended,” and only the treatment team should decide when therapy resumes.
Understanding the Six-Day Leqembi Missed-Dose Window
The six-day window preserves the original weekly schedule. Suppose an injection is normally due every Tuesday. If it is given late on Friday, the next prescribed injection remains Tuesday; the family does not automatically move all future doses to Friday. Even when the catch-up dose is given on Monday—six days after the scheduled Tuesday—the prescribing instructions say to administer the next dose on the regularly scheduled day. That timing can produce two doses on consecutive days at the edge of the permitted window, which may feel counterintuitive.
Families should follow the dispensing label and the treatment team’s instructions rather than applying missed-dose rules from another weekly medicine. If the patient’s clinician has supplied individualized directions, those directions take priority because the prescriber may know about recent symptoms, MRI findings, medication changes, or treatment interruptions that alter the plan. Once more than six days have passed, the approved catch-up instruction no longer states that families should administer the missed dose at home. Call the neurology office, infusion program, or on-call clinician and report the exact dates. Do not combine doses, use an extra autoinjector, or assume that waiting until the next regular day is correct without professional guidance. The limitation is important: the six-day rule is a defined dosing instruction, not permission to independently redesign the regimen.
When a Missed Injection Is Really a Safety Hold
Leqembi can cause amyloid-related imaging abnormalities, or ARIA, involving swelling or bleeding in or around the brain. ARIA frequently produces no noticeable symptoms, but it can be serious or fatal. Warning symptoms include a new or worsening headache, confusion, dizziness, vision changes, nausea, difficulty walking, weakness, difficulty speaking, or seizures. The FDA advises patients and caregivers to contact a healthcare professional or go to an emergency department immediately when these symptoms occur. A missed injection should not distract the family from a possible neurological emergency. For example, consider a person who missed Saturday’s injection and develops unusual confusion and an unsteady gait on Sunday.
The family should not simply give the delayed injection and wait to see whether the symptoms improve. They should seek urgent medical evaluation and tell the clinical team that the patient receives Leqembi because ARIA symptoms can resemble a stroke. The FDA's Leqembi safety communication specifically advises immediate evaluation for symptoms such as headache, confusion, dizziness, vision changes, nausea, walking difficulty, or seizures. The same caution applies when a dose was missed because the patient was hospitalized, fell, developed a severe infection, or began a blood thinner. Families should not stop or restart anticoagulants on their own, but they should tell the Leqembi prescriber about new medicines and medical events before catching up. Anticoagulant use and other bleeding risks may affect the clinician’s assessment because intracerebral hemorrhage has occurred during Leqembi treatment.
A Practical Family Plan for Missed Leqembi Doses
A written dosing plan should name one person responsible for confirming each injection and one backup caregiver. Record the scheduled date, actual administration time, injection site, number of devices used, and any reaction. If the prescribed dose requires more than one autoinjector and only part of the dose may have been administered, stop and call the prescriber rather than guessing how much medication entered the body. Electronic reminders are convenient, but a shared phone alert can create confusion if several people dismiss it. A paper log beside the medication storage area gives caregivers a visible record but may not help a relative who is away from home.
Many families benefit from using both: a calendar alert prompts the task, while a signed entry confirms completion. The tradeoff is a little extra documentation in exchange for reducing both missed and duplicate doses. The family’s written plan should also include the neurology office number, specialty pharmacy number, after-hours contact, regular injection day, and instructions for weekends or holidays. A Friday-night discovery can otherwise lead to an unsafe choice between waiting several days and injecting without reliable information. Planning does not replace clinical advice, but it makes the information needed for that advice immediately available.
Common Leqembi Injection Problems That Need a Clinician’s Advice
Uncertainty about whether the full dose was delivered is a common reason to pause. The autoinjector may have been lifted too soon, medication may appear on the skin, or a person with cognitive impairment may remove the device during administration. Do not immediately repeat the injection. The visible liquid does not reliably show how much medicine entered the body, and repeating a possibly completed dose could result in unintended additional medication. Injection-site redness, swelling, warmth, itching, pain, rash, bruising, or a small collection of blood under the skin can occur.
Record when the reaction began and, if practical, take a photograph for the clinician. Seek urgent help for swelling of the face, lips, mouth, or tongue, hives, difficulty breathing, or other signs of a serious allergic reaction. A severe reaction is not an ordinary missed-dose issue, and the next injection should not be given until a clinician has assessed the situation. Families should also call before giving a late dose if the patient has new neurological symptoms, recently had an abnormal MRI, was told to suspend treatment, started an anticoagulant, or has been hospitalized since the last dose. Scheduled MRI monitoring remains necessary even when injections are given at home. The FDA's announcement about at-home Leqembi initiation emphasizes that the subcutaneous option retains Leqembi’s boxed warning about ARIA and intracerebral hemorrhage.
Storage and Autoinjector Problems Can Create a Missed Dose
A dose should not be given from an autoinjector that is damaged, has been dropped, appears cloudy or contains visible particles, has frozen, or was stored outside its permitted conditions. Leqembi IQLIK is normally refrigerated in its original carton to protect it from light. Approved patient instructions allow limited room-temperature storage, but once an autoinjector has been brought to room temperature, it should not be returned to the refrigerator.
Families should check the current package instructions because formulations and supplied devices may change. For example, after a prolonged power outage, a caregiver may be unable to confirm how warm the refrigerator became or for how long. Giving the questionable product to avoid a missed dose is not the safe workaround. Keep the device available, note the outage period and estimated temperature, and contact the specialty pharmacy or manufacturer for product-specific instructions and replacement options.
What Emergency Teams Need to Know About Leqembi
Patients should carry a medication card stating that they receive lecanemab-irmb, the route of administration, the date of the last completed dose, and the prescriber’s contact information. Emergency clinicians need to know about Leqembi because ARIA can resemble ischemic stroke, and decisions involving anticoagulant or clot-dissolving medicines may require additional caution and imaging.
If a patient arrives at the emergency department after a missed injection with weakness, speech difficulty, seizure, severe headache, or sudden confusion, the caregiver should report the regular dosing day, whether a catch-up dose was attempted, all blood thinners or antiplatelet medicines, and any recent MRI findings. A concrete entry such as “Leqembi injection scheduled Monday, not given; symptoms began Wednesday at 10:15 a.m.; last completed dose was the previous Monday” is more useful than saying only that treatment was missed.
Frequently Asked Questions
Can a family give a missed Leqembi IQLIK injection the next day?
Yes, the approved instructions say to give a confirmed missed subcutaneous dose as soon as possible within six days of the scheduled date, then return to the original dosing day, unless the clinician has placed treatment on hold.
Should the regular injection day change after a catch-up dose?
No. The prescribing instructions say the next injection should occur on the regularly scheduled day. Do not permanently shift the schedule unless the prescriber directs that change.
What should happen if more than six days have passed?
Contact the prescribing clinician before giving the missed dose. The approved home catch-up instruction covers only the first six days after the scheduled dose.
What if no one knows whether the injection was already given?
Treat the situation as an uncertain dose, not a confirmed missed dose. Check the treatment log and used-device container, then call the prescriber or specialty pharmacy rather than risking a duplicate injection.
Does the same missed-dose rule apply to intravenous Leqembi?
No. For a missed intravenous infusion, the prescribing information directs that the next dose be administered as soon as possible, but the infusion center and prescriber must arrange the treatment schedule.
Should a delayed injection be given when the patient has a new headache or confusion?
New or worsening headache, confusion, dizziness, vision changes, nausea, walking difficulty, weakness, speech difficulty, or seizures require immediate medical attention because they may indicate ARIA or another neurological emergency.
